SCHEMBL16474763

SCHEMBL16474763

O=c1ccc(-c2cn[nH]c2)cn1-c1cccc(C(F)(F)F)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.51
MKNK1 Q9BUB5 2/20 0.44
MKNK2 Q9HBH9 2/20 0.44
ROCK2 O75116 2/20 0.44
CYP1A2 P05177 1/20 0.43
EPHB4 P54760 1/20 0.42
NPBWR1 P48145 1/20 0.42
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
MAPT P10636 2/20 0.40
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
TEK Q02763 1/20 0.40
POLB P06746 1/20 0.40
GAA P10253 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
EPHX2 P34913 1/20 0.40
XDH P47989 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16474758 0.84 ROCK2 (0.48) MKNK1MKNK2ROCK2
SCHEMBL10059575 0.83 AKT2 (0.51) ROCK2CYP1A2KDM4EALDH1A1
SCHEMBL13635428 0.81 KDR (0.48) ROCK2CYP1A2KMT2AMAPTKDM4E
SCHEMBL18077736 0.81 ROCK2 (0.43) ROCK2EPHB4TEK
SCHEMBL16474677 0.81 HTT (0.49) HTTCYP1A2KMT2AMAPTKDM4E
SCHEMBL16474759 0.81 ROCK2 (0.53) ROCK2
SCHEMBL16474671 0.80 HTT (0.48) HTTMKNK1MKNK2CYP1A2MEN1
SCHEMBL16474764 0.78 ROCK2 (0.48) ROCK2
SCHEMBL16474687 0.78 MEN1 (0.50) HTTCYP1A2NPBWR1MEN1KMT2A
SCHEMBL16474760 0.78 ABL1 (0.47) ROCK2EPHB4POLBL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2903991-B1 ANTI-FIBROTIC PYRIDINONES INTERMUNE INC (US) 2020-09-16 EP disclosed
US-10544161-B2 Anti-fibrotic pyridinones INTERMUNE, INC. (US) 2020-01-28 US disclosed
US-20190321343-A1 Anti-Fibrotic Pyridinones GENENTECH, INC. 2019-10-24 US disclosed
US-10376497-B2 Anti-fibrotic pyridinones INTERMUNE, INC. (US) 2019-08-13 US disclosed
US-20190144467-A1 ANTI-FIBROTIC PYRIDINONES GENENTECH, INC. 2019-05-16 US disclosed
US-10233195-B2 Anti-fibrotic pyridinones INTERMUNE, INC. (US) 2019-03-19 US disclosed
US-20180064692-A1 Anti-Fibrotic Pyridinones GENENTECH, INC. 2018-03-08 US disclosed
US-20180064692-A1 Anti-Fibrotic Pyridinones GENENTECH, INC. 2018-03-08 US disclosed
US-9675593-B2 Anti-fibrotic pyridinones INTERMUNE, INC. (US) 2017-06-13 US disclosed
US-9675593-B2 Anti-fibrotic pyridinones INTERMUNE, INC. (US) 2017-06-13 US disclosed
US-20170121345-A1 ANTI-FIBROTIC PYRIDINONES GENENTECH, INC. 2017-05-04 US disclosed
US-20170121345-A1 ANTI-FIBROTIC PYRIDINONES GENENTECH, INC. 2017-05-04 US disclosed
US-20160263090-A1 ANTI-FIBROTIC PYRIDINONES GENENTECH, INC. 2016-09-15 US disclosed
US-9359379-B2 Anti-fibrotic pyridinones INTERMUNE, INC. (US) 2016-06-07 US disclosed
US-9359379-B2 Anti-fibrotic pyridinones INTERMUNE, INC. (US) 2016-06-07 US disclosed
WO-2015153683-A1 ANTI-FIBROTIC PYRIDINONES INTERMUNE, INC. (US) 2015-10-08 WO disclosed
US-20140107110-A1 ANTI-FIBROTIC PYRIDINONES GENENTECH, INC. 2014-04-17 US disclosed
US-20140107110-A1 ANTI-FIBROTIC PYRIDINONES GENENTECH, INC. 2014-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180064692-A1 Anti-Fibrotic Pyridinones MMP1, COL1A1, COL2A1 HTT 4516/4885MKNK1 3297/4885MKNK2 2924/4885
US-10544161-B2 Anti-fibrotic pyridinones MMP1, COL1A1, COL2A1 HTT 4516/4885MKNK1 3297/4885MKNK2 2924/4885
US-20190321343-A1 Anti-Fibrotic Pyridinones MMP1, COL1A1, COL2A1 HTT 4516/4885MKNK1 3297/4885MKNK2 2924/4885
US-20140107110-A1 ANTI-FIBROTIC PYRIDINONES MMP1, COL1A1, COL2A1 HTT 4516/4885MKNK1 3297/4885MKNK2 2924/4885
US-20160263090-A1 ANTI-FIBROTIC PYRIDINONES MMP1, COL1A1, COL2A1 HTT 4516/4885MKNK1 3297/4885MKNK2 2924/4885
US-10233195-B2 Anti-fibrotic pyridinones MMP1, COL1A1, COL2A1 HTT 4516/4885MKNK1 3297/4885MKNK2 2924/4885
US-10376497-B2 Anti-fibrotic pyridinones MMP1, COL1A1, COL2A1 HTT 4516/4885MKNK1 3297/4885MKNK2 2924/4885
US-20170121345-A1 ANTI-FIBROTIC PYRIDINONES MMP1, COL1A1, COL2A1 HTT 4516/4885MKNK1 3297/4885MKNK2 2924/4885
US-20190144467-A1 ANTI-FIBROTIC PYRIDINONES MMP1, COL1A1, COL2A1 HTT 4516/4885MKNK1 3297/4885MKNK2 2924/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.